Concepedia

Author

Antonietta Falcone

Istituti di Ricovero e Cura a Carattere Scientifico

Also Known As

A Falcone, A P Falcone, A. Falcone, A. P. Falcone, A.P. Falcone, ANTONIETTA FALCONE, Antonietta FALCONE, Antonietta Falcone, Antonietta P. Falcone, Antonietta Pia Falcone

216

Publications

5.4K

Citations

35

H-Index

54

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoCasa Sollievo della SofferenzaCentro di Riferimento Oncologico della BasilicataAzienda Ospedaliero Universitaria San Giovanni BattistaFondazione Gimema Onlus
AF

About

Antonietta Falcone is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

28

935

2

Health Sciences

12

14

516

3

Nursing

1

1

21

4

Allergy

1

1

21

5

Blood Transplantation

1

1

10

Antonietta Falcone

×

77

Publications

4.7K

Citations

34

H-Index

YearCitations

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli,

Journal of Clinical Oncology

2010

424

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Alessandra Larocca, Davide Rossi, Maide Cavalli,

Blood

2010

379

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Antonio Palumbo, Sara Bringhen, Anna Marina Liberati,

Blood

2008

357

Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

Antonio Palumbo, Patrizia Falco, Paolo Corradini,

Journal of Clinical Oncology

2007

316

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michèle Cavo, Lucia Pantani, Maria Teresa Petrucci,

Blood

2012

309

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Antonio Palumbo, Sara Bringhen, Alessandra Larocca,

Journal of Clinical Oncology

2014

210

Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial

Monia Marchetti, Giovanni Barosi, Francesca Balestri,

Journal of Clinical Oncology

2004

144

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

Antonio Palumbo, Francesca Gay, Sara Bringhen,

Annals of Oncology

2008

126

Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.

Giovanni Barosi, Achille Ambrosetti, Antonietta Centra,

PubMed

1998

121

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

Giovanni D’Arena, Paolo G. Gobbi, Chiara Broglia,

Leukemia & lymphoma/Leukemia and lymphoma

2011

99

Page 1